Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Testosterone and ill-health in aging men

Nature Clinical Practice Endocrinology & Metabolism volume 5, pages 113–121 (2009)Cite this article

Abstract

As men age, testosterone levels decline, and decreased testosterone levels are associated with increased risks of osteoporosis, metabolic syndrome, type 2 diabetes mellitus and mortality. Nevertheless, it is still uncertain whether reduced testosterone level is a cause of ill-health or a marker of pre-existing disease, as systemic illness lowers testosterone levels. Most circulating testosterone is bound to sex-hormone-binding globulin (SHBG) and albumin, whereas a small proportion circulates as free testosterone. Decreased SHBG level is associated with increased risks for insulin resistance and metabolic syndrome, although it would also be expected to be associated with increased free testosterone level. During male aging, total and free testosterone levels fall while SHBG level rises. Thus, associations between decreasing androgens and negative health outcomes might differ across men of various ages. Trials of testosterone therapy report benefits for body composition and BMD, but there are limited data on the effect of testosterone supplementation on cardiovascular risk. Whereas men who have androgen deficiency should be considered for testosterone therapy, the role of testosterone supplementation in older men who are not clearly hypogonadal requires further clarification. Further studies are also needed to establish whether the age-related decline in circulating testosterone level in men can be modified or prevented.

Key Points

  • Declining testosterone levels are a central feature of hormonal changes that occur during aging in men

  • Decreased testosterone levels are associated with negative health outcomes; however, a causal relationship is difficult to establish as systemic illness can reduce testosterone levels

  • A decreased level of sex-hormone-binding globulin modulates the availability of free testosterone in the circulation, and might be associated with cardiovascular risk independently of testosterone

  • Randomized, controlled clinical trials have found a favorable effect of testosterone supplementation on body composition and BMD in men with low-to-normal testosterone levels, with more marginal influences on general and sexual health

  • Further studies are needed to clarify the role of testosterone supplementation in aging men who are not clearly hypogonadal, and to determine the feasibility of interventions to modify or prevent the age-related decline in testosterone levels in men

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Changes in testosterone levels during aging in men.

Similar content being viewed by others

References

  1. Ferrini RL and Barrett-Connor E (1998) Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Am J Epidemiol 147: 750–754

    CAS  PubMed  Google Scholar 

  2. Svartberg J et al. (2003) The associations of age, lifestyle factors and chronic disease with testosterone in men: the Tromso study. Eur J Endocrinol 149: 145–152

    CAS  PubMed  Google Scholar 

  3. Muller M et al. (2003) Endogenous sex hormones in men aged 40-80 years. Eur J Endocrinol 149: 583–589

    CAS  PubMed  Google Scholar 

  4. Litman HJ et al. (2006) Serum androgen levels in black, Hispanic, and white men. J Clin Endocrinol Metab 91: 4326–4334

    CAS  PubMed  Google Scholar 

  5. Morley JE et al. (1997) Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 46: 410–413

    CAS  PubMed  Google Scholar 

  6. Harman SM et al. (2001) Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 86: 724–731

    CAS  PubMed  Google Scholar 

  7. Feldman HA et al. (2002) Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 87: 589–598

    CAS  PubMed  Google Scholar 

  8. Liu PY et al. (2007) Age-related changes in serum testosterone and sex hormone binding globulin in Australian men: longitudinal analyses of two geographically separate regional cohorts. J Clin Endocrinol Metab 92: 3599–3603

    CAS  PubMed  Google Scholar 

  9. Vermeulen A et al. (1996) Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. J Clin Endocrinol Metab 81: 1821–1826

    CAS  PubMed  Google Scholar 

  10. Orwoll E et al. (2006) Testosterone and estradiol in older men. J Clin Endocrinol Metab 91: 1336–1344

    CAS  PubMed  Google Scholar 

  11. Yeap BB et al. (2007) In men older than 70 years, total testosterone remains stable while free testosterone declines with age. The Health In Men Study. Eur J Endocrinol 156: 585–594

    CAS  PubMed  Google Scholar 

  12. Barrett-Connor E et al. (1999) Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J Clin Endocrinol Metab 84: 573–577

    CAS  PubMed  Google Scholar 

  13. Eriksson AL et al. (2006) SHBG gene promoter polymorphisms in men are associated with serum sex hormone-binding globulin, androgen and androgen metabolite levels, and hip bone mineral density. J Clin Endocrinol Metab 91: 5029–5037

    CAS  PubMed  Google Scholar 

  14. Veldhuis JD (2008) Aging and hormones of the hypothalamo-pituitary axis: gonadotropic axis in men and somatotropic axes in men and women. Ageing Res Rev 7: 189–208

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Bhasin S (2008) Testicular disorders. In Williams Textbook of Endocrinology, edn 11, 645–699 (Eds Kronenberg HM. et al.) Philadelphia: Saunders Elsevier

    Google Scholar 

  16. Svartberg J et al. (2008) Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res 20: 378–387

    CAS  PubMed  Google Scholar 

  17. Schaap LA et al. (2005) The association of sex hormone levels with poor mobility, low muscle strength and incidence of falls among older men and women. Clin Endocrinol 63: 152–160

    CAS  Google Scholar 

  18. O'Donnell AB et al. (2006) Testosterone, dehydroepiandrosterone, and physical performance in older men: results from the Massachussetts Male Aging Study. J Clin Endocrinol Metab 91: 425–431

    CAS  PubMed  Google Scholar 

  19. Allan CA et al. (2008) Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab 93: 139–146

    CAS  PubMed  Google Scholar 

  20. Page ST et al. (2005) Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 90: 1502–1510

    CAS  PubMed  Google Scholar 

  21. Fink HA et al. (2006) Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab 91: 3908–3915

    CAS  PubMed  Google Scholar 

  22. Meier C et al. (2008) Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med 168: 47–54

    CAS  PubMed  Google Scholar 

  23. Araujo AB et al. (2008) Correlations between serum testosterone, estradiol, and sex hormone-binding globulin and bone mineral density in a diverse sample of men. J Clin Endocrinol Metab 93: 2135–2141

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Isidori AM et al. (2005) Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol 63: 280–293

    CAS  Google Scholar 

  25. Tracz MJ et al. (2006) Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab 91: 2011–2016

    CAS  PubMed  Google Scholar 

  26. Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285: 2486–2497

  27. Alberti KG et al. (2006) Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 23: 469–480

    CAS  PubMed  Google Scholar 

  28. Muller M et al. (2005) Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 90: 2618–2623

    CAS  PubMed  Google Scholar 

  29. Maggio M et al. (2006) Association between hormones and metabolic syndrome in older Italian men. J Am Geriatr Soc 54: 1832–1838

    PubMed  PubMed Central  Google Scholar 

  30. Chubb SA et al. (2008) Lower sex hormone binding globulin is more strongly associated with metabolic syndrome than lower total testosterone in older men: the Health In Men Study. Eur J Endocrinol 158: 785–792

    CAS  PubMed  Google Scholar 

  31. Kupelian V et al. (2006) Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 91: 843–850

    CAS  PubMed  Google Scholar 

  32. Laaksonen DE et al. (2004) Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27: 1036–1041

    CAS  PubMed  Google Scholar 

  33. Rodriguez A et al. (2007) Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 92: 3568–3572

    CAS  PubMed  Google Scholar 

  34. Selvin E et al. (2007) Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 30: 234–238

    CAS  PubMed  Google Scholar 

  35. Ding EL et al. (2006) Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 295: 1288–1299

    CAS  PubMed  Google Scholar 

  36. Oh JY et al. (2002) Endogenous sex hormones and the development of T2DM in older men and women: the Rancho Bernardo study. Diabetes Care 25: 55–60

    CAS  PubMed  Google Scholar 

  37. Grossmann M et al. (2008) Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab 93: 1834–1840

    CAS  PubMed  Google Scholar 

  38. Tsai EC et al. (2004) Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat. Diabetes Care 27: 861–868

    CAS  PubMed  Google Scholar 

  39. Pitteloud N et al. (2005) Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 28: 1636–1642

    CAS  PubMed  Google Scholar 

  40. Bonora E et al. (2007) Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population: the Bruneck study. Diabetes Care 30: 318–324

    PubMed  Google Scholar 

  41. de Simone G et al. (2007) Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study. Diabetes Care 30: 1851–1856

    PubMed  Google Scholar 

  42. Saely CH et al. (2005) The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. J Clin Endocrinol Metab 90: 5698–5703

    CAS  PubMed  Google Scholar 

  43. Lorenz MW et al. (2007) Prediction of clinical cardiovascular events with carotid intima–media thickness: a systematic review and meta-analysis. Circulation 115: 459–467

    PubMed  Google Scholar 

  44. Makinen J et al. (2005) Increased carotid atherosclerosis in andropausal middle-aged men. J Am Coll Cardiol 45: 1603–1608

    PubMed  Google Scholar 

  45. van den Beld AW et al. (2003) Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol 157: 25–31

    CAS  PubMed  Google Scholar 

  46. Muller M et al. (2004) Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation 109: 2074–2079

    CAS  PubMed  Google Scholar 

  47. Hak AE et al. (2002) Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab 87: 3632–3639

    CAS  PubMed  Google Scholar 

  48. Tivesten A et al. (2007) Low serum testosterone and high serum estradiol associate with lower extremity peripheral arterial disease in elderly men. The MrOS Study in Sweden. J Am Coll Cardiol 50: 1070–1076

    CAS  PubMed  Google Scholar 

  49. Kaufman JM and Vermeulen A (2005) The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 26: 833–876

    CAS  PubMed  Google Scholar 

  50. Karagiannis A and Harsoulis F (2005) Gonadal dysfunction in systemic diseases. Eur J Endocrinol 152: 501–513

    CAS  PubMed  Google Scholar 

  51. Cauley JA et al. (1987) Usefulness of sex steroid hormone levels in predicting coronary artery disease in men. Am J Cardiol 60: 771–777

    CAS  PubMed  Google Scholar 

  52. Barrett-Connor E and Khaw KT (1988) Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 78: 539–545

    CAS  PubMed  Google Scholar 

  53. Yarnell JW et al. (1993) Endogenous sex hormones and ischemic heart disease in men. The Caerphilly prospective study. Arterioscler Thromb 13: 517–520

    CAS  PubMed  Google Scholar 

  54. Liverman CT and Blazer DG (Eds, 2004) Testosterone and Aging: Clinical Research Directions. Washington, DC, USA: The National Academy Press

    Google Scholar 

  55. Haddad RM et al. (2007) Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 82: 29–39

    CAS  PubMed  Google Scholar 

  56. Yki-Jarvinen H et al. (1995) Portal insulin concentrations rather than insulin sensitivity regulate serum sex hormone-binding globulin and insulin-like growth factor binding protein 1 in vivo. J Clin Endocrinol Metab 80: 3227–3232

    CAS  PubMed  Google Scholar 

  57. Osuna JA et al. (2006) Relationship between BMI, total testosterone, sex hormone-binding-globulin, leptin, insulin and insulin resistance in obese men. Arch Androl 52: 355–361

    CAS  PubMed  Google Scholar 

  58. Haffner SM et al. (1996) Low levels of sex hormone-binding globulin and testosterone are associated with smaller, denser low density lipoprotein in normoglycemic men. J Clin Endocrinol Metab 81: 3697–3701

    CAS  PubMed  Google Scholar 

  59. Kalme T et al. (2005) Sex hormone-binding globulin and insulin-like growth factor-binding protein-1 as indicators of metabolic syndrome, cardiovascular risk, and mortality in elderly men. J Clin Endocrinol Metab 90: 1550–1556

    CAS  PubMed  Google Scholar 

  60. Goodman-Gruen D and Barrett-Connor E (1996) A prospective study of sex hormone-binding globulin and fatal cardiovascular disease in Rancho Bernardo men and women. J Clin Endocrinol Metab 81: 2999–3003

    CAS  PubMed  Google Scholar 

  61. Shores MM et al. (2006) Low serum testosterone and mortality in male veterans. Arch Intern Med 166: 1660–1665

    CAS  PubMed  Google Scholar 

  62. Khaw KT et al. (2007) Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men. European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 116: 2694–2701

    CAS  PubMed  Google Scholar 

  63. Laughlin GA et al. (2008) Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 93: 68–75

    CAS  PubMed  Google Scholar 

  64. Smith GD et al. (2005) Cortisol, testosterone and coronary heart disease. Prospective evidence from the Caerphilly Study. Circulation 112: 332–340

    CAS  PubMed  Google Scholar 

  65. Araujo AB et al. (2007) Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med 167: 1252–1260

    CAS  PubMed  Google Scholar 

  66. Arnlov J et al. (2006) Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med 145: 176–184

    CAS  PubMed  Google Scholar 

  67. Araujo AB et al. (2004) Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 89: 5920–5926

    CAS  PubMed  Google Scholar 

  68. Araujo AB et al. (2007) Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 92: 4241–4247

    CAS  PubMed  Google Scholar 

  69. Travison TG et al. (2008) The natural history of symptomatic androgen deficiency in men: onset, progression, and spontaneous remission. J Am Geriatr Soc 56: 831–839

    PubMed  PubMed Central  Google Scholar 

  70. Liu PY et al. (2004) The rationale, efficacy and safety of androgen therapy in older men: future research and current practice recommendations. J Clin Endocrinol Metab 89: 4789–4796

    CAS  PubMed  Google Scholar 

  71. Bhasin S et al. (2006) Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 91: 1995–2010

    CAS  PubMed  Google Scholar 

  72. Conway AJ et al. (2000) Use, misuse and abuse of androgens. The Endocrine Society of Australia consensus guidelines for androgen prescribing. Med J Aust 172: 220–224

    CAS  PubMed  Google Scholar 

  73. Nieschlag E et al. (2006) Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. J Androl 27: 135–137

    CAS  PubMed  Google Scholar 

  74. Yeap BB et al. (2008) Higher serum free testosterone is associated with better cognitive function in older men, while total testosterone is not. The Health In Men Study. Clin Endocrinol 68: 404–412

    CAS  Google Scholar 

  75. Almeida OP et al. (2008) Low free testosterone concentration as a potentially treatable cause of depressive symptoms in older men. Arch Gen Psychiatry 65: 283–289

    CAS  PubMed  Google Scholar 

  76. Vermeulen A et al. (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84: 3666–3672

    CAS  PubMed  Google Scholar 

  77. Rosner W et al. (2007) Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 92: 405–413

    CAS  PubMed  Google Scholar 

  78. Wu FC et al. (2008) Hypothalamic–pituitary–testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 93: 2737–2745

    CAS  PubMed  Google Scholar 

  79. Svartberg J et al. (2004) Waist circumference and testosterone levels in community dwelling men. The Tromso study. Eur J Epidemiol 9: 657–663

    Google Scholar 

  80. Mohr BA et al. (2006) The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts Male Aging Study. Eur J Endocrinol 155: 443–452

    CAS  PubMed  Google Scholar 

  81. Travison TG et al. (2007) The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab 92: 549–555

    CAS  PubMed  Google Scholar 

  82. Allen NE et al. (2002) Lifestyle and nutritional determinants of bioavailable androgens and related hormones in British men. Cancer Causes Control 13: 353–363

    PubMed  Google Scholar 

  83. Wu AH et al. (1995) Serum androgens and sex-hormone binding globulins in relation to lifestyle factors in older African-American, White, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev 4: 735–741

    CAS  PubMed  Google Scholar 

  84. Wong SYS et al. (2006) Prevalence of and risk factors for androgen deficiency in middle-aged men in Hong Kong. Metabolism 55: 1488–1494

    CAS  PubMed  Google Scholar 

  85. Yeap BB et al. (2008) Healthier lifestyle predicts higher circulating testosterone in older men. The Health In Men Study. Clin Endocrinol [10.1111/j.1365-2265.2008.03372.x]

  86. Travison TG et al. (2007) A population-level decline in serum testosterone levels in American men. J Clin Endocrinol Metab 92: 196–202

    CAS  PubMed  Google Scholar 

  87. Andersson AM et al. (2007) Secular decline in male testosterone and sex hormone binding globulin serum levels in Danish population surveys. J Clin Endocrinol Metab 92: 4696–4705

    CAS  PubMed  Google Scholar 

  88. Yeap BB et al. (2004) The androgen receptor mRNA. Bioessays 26: 672–682

    CAS  PubMed  Google Scholar 

  89. Rahman F and Christian HC (2007) Non-classical actions of testosterone: an update. Trends Endocrinol Metab 18: 371–378

    CAS  PubMed  Google Scholar 

  90. Jones ME et al. (2007) Recognizing rare disorders: aromatase deficiency. Nat Clin Pract Endocrinol Metab 3: 414–421

    CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. School of Medicine and Pharmacology, Level 2, T Block, Fremantle Hospital, Alma Street, Fremantle, WA 6160, Australia byeap@cyllene.uwa.edu.au

Authors and Affiliations

  1. and is the Head of the Department of Endocrinology and Diabetes, BB Yeap is an Associate Professor at the School of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital, WA, Australia.,

    Bu B Yeap

Authors
  1. Bu B Yeap
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author has declared an association with the following company: Bayer Healthcare (speakers bureau).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yeap, B. Testosterone and ill-health in aging men. Nat Rev Endocrinol 5, 113–121 (2009). https://doi.org/10.1038/ncpendmet1050

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet1050

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing